Scientific Evidence, Regulatory Decision Making, and Incentives for Therapeutics in Infectious Diseases: The Example of Cefiderocol
- PMID: 33257939
- DOI: 10.1093/cid/ciaa1795
Scientific Evidence, Regulatory Decision Making, and Incentives for Therapeutics in Infectious Diseases: The Example of Cefiderocol
Comment on
-
US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®).Clin Infect Dis. 2021 Jun 15;72(12):e1103-e1111. doi: 10.1093/cid/ciaa1799. Clin Infect Dis. 2021. PMID: 33393598 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
